Lymphoma Clinical Trials

Showing 1401-1420 of 3,379 trials

Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse

NCT03229382

The objective of the study is the evaluation of efficacy and safety of obinutuzumab preemptive treatment at the time of the molecular relapse after first line immunochemotherapy with autologous stem cell transplantation in mantle cell lymphoma patients.

Mantle Cell Lymphoma

Polish Lymphoma Research Group1 participantsStarted May 2018

Warsaw, Poland

COMPLETED

Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma

NCT00903890

This study is to inquire by mailed survey regarding the cardiac and general health of patients previously treated for Hodgkin's and non-Hodgkin's lymphoma with radiation therapy/anthracycline chemotherapy.

Hodgkin DiseaseLymphoma, Non-Hodgkin

University of Rochester32 participantsStarted Aug 2008

Rochester, New York, United States

TERMINATEDPhase 3

Dose Optimization Study of Idelalisib in Follicular Lymphoma

NCT02536300

The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.

Follicular Lymphoma

Gilead Sciences96 participantsStarted Jan 2016

Woodville South, South Australia, Australia • Barrie, Canada • Brno, Czechia +63 more locations

Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse

Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Related Searches

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

Bortezomib in Treating Patients With Mantle Cell Lymphoma

AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Obinutuzumab in Chinese Real-world Patients With iNHL

Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Construction of Diagnosis and Treatment System for Primary Vitreoretinal Lymphoma

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

FDG-PET/CT Imaging as Early Predictor of DP

TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL